L-Carnosine
PreclinicalSmall molecule
L-Carnosine is one of 121 small molecule programs targeting Bipolar I Disorder. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
120
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Celexa
AbbViePreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Catapres
Boehringer IngelheimPreclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Compazine
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Peripheral Neuropathy1 trial
L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients
Completed·—·Phase 1/2·NCT02808624·65 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-Carnosine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pittsburgh